PrEP as Safe as Aspirin, Claims New Study

A study recently published in the Oxford Journal's Open Forum Infectious Diseases concluded that taking pre-exposure propyhlaxis for the prevention of HIV was as safe as aspirin.

Researchers from the University of California, Los Angeles compared five major studies on PrEP for HIV infection and two major studies on aspirin safety.

According to the study, catchily titled, "Is Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis for the Prevention of HIV Infection Safer than Aspirin?":

...PrEP for HIV infection favorably compares to aspirin in terms of user safety. While long-term studies are needed, providers should feel reassured about the safety of short- and medium-term PrEP for HIV infection with FTC-TDF.

While numerous studies have proven the efficacy of PrEP, there have been concerns over the drugs side effects, which can include nausea and untintentional weight loss.

Related | New PrEP Study Reinforces Drug's High Effectiveness

For more information on PrEP and how to get on it, click here.